ReviewSeminars in immunopathology2009
Progressive multiple sclerosis.
Review in Seminars in immunopathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 110 citations in OpenAlex.
- Flow cytometric analysis reveals the high levels of platelet activation parameters in circulation of multiple sclerosis patients.Molecular and cellular biochemistry · 2017Trial
- Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.BMC neurology · 2012Trial
- Transport pathways across the blood-brain barrier for waste clearance and drug delivery.Fluids and barriers of the CNS · 2026Review
- Pediatric-Onset Multiple Sclerosis (POMS) and Epilepsy: Exploring Etiological Complexity-Outcomes from a Single-Center Experience.Children (Basel, Switzerland) · 2025Article
- Ferroptosis induces detrimental effects in chronic EAE and its implications for progressive MS.Acta neuropathologica communications · 2023Article
- Neuroinflammation and Mitochondrial Dysfunction in Parkinson's Disease: Connecting Neuroimaging with Pathophysiology.Antioxidants (Basel, Switzerland) · 2023Review
- [Neuropsychological and MRI diagnostics in secondary progressive multiple sclerosis].Der Nervenarzt · 2021Review
- Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy.Brain sciences · 2020Article
- Impact of B cells to the pathophysiology of multiple sclerosis.Journal of neuroinflammation · 2019Review
- Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.Molecular neurobiology · 2017Article
- Ongoing Oxidative Stress Causes Subclinical Neuronal Dysfunction in the Recovery Phase of EAE.Frontiers in immunology · 2016Article
- A review of genome-wide association studies for multiple sclerosis: classical and hypothesis-driven approaches.Human genetics · 2015Review
- Relationship between the Increased Haemostatic Properties of Blood Platelets and Oxidative Stress Level in Multiple Sclerosis Patients with the Secondary Progressive Stage.Oxidative medicine and cellular longevity · 2015Article
- Multicontrast MRI Quantification of Focal Inflammation and Degeneration in Multiple Sclerosis.BioMed research international · 2015Article
- Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.PloS one · 2014Article
- 7 Tesla magnetic resonance imaging to detect cortical pathology in multiple sclerosis.PloS one · 2014Article
- Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned.Frontiers in cellular neuroscience · 2014Review
- Disease-modifying therapies for nonrelapsing multiple sclerosis: Costs and benefits of medical intervention.Neurology. Clinical practice · 2013Article
- Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.Therapeutic advances in neurological disorders · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease of the central nervous system, which starts in the majority of patients with a relapsing/remitting MS (RRMS) course , which after several years of disease duration converts into a progressive disease. Since anti-inflammatory therapies and immune modulation exert a beneficial effect at the relapsing/remitting stage of the disease, but not in the progressive stage, the question was raised whether inflammation drives tissue damage in progressive MS at all. We show here that also in progressive MS, inflammation is the driving force for brain injury and that the discrepancy between inflammation-driven tissue injury and response to immunomodulatory therapies can be explained by different pathomechanisms acting in RRMS and progressive MS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.